Company / Shareholders' Equity
Revolution Medicines, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$1.6B
FY2025
5-year range
-$152.6M / $2.3B
FY2021-FY2025
Trend
-28.0%
vs FY2024
Sector context
#31 of 213
Health Care
What the data says
Revolution Medicines, Inc.'s shareholders' equity of $1.6B is higher than 85% of companies in the Health Care sector (FY2025). Shareholders' Equity has fluctuated over the past 8 years, ranging from -$153M in FY2021 to $2.3B in FY2024.
Based on SEC 10-K filings.
$1.6B in FY2025 with a 3-year CAGR of +50.9%. Top quartile in the Health Care sector.
Declined from $1.8B to $1.6B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +50.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-36.0% below sector average
Key checks
Key Insights
- 3-year CAGR of +50.9%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 28.0% year-over-year.
- Ranks #31 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.6B | -28.0% |
| FY2024 | $2.3B | +24.0% |
| FY2023 | $1.8B | +284.7% |
| FY2022 | $474.7M | +411.1% |
| FY2021 | -$152.6M | -40.7% |
| FY2020 | -$108.4M | +28.9% |
| FY2019 | -$152.6M | -40.7% |
| FY2018 | -$108.4M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026